Rigel Reports First Quarter 2021 Financial Results and Provides Business Update
- Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19
- Net product sales of $12.4 million and total revenues of $81.0 million
- Received upfront cash payment of $125 million from Eli Lilly for the exclusive license agreement for Rigel s RIP1 inhibitor program
- Conference call and webcast today at 4:30PM Eastern Time
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million
- Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel s RIP1 inhibitor program
- Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients
- Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021
- Conference call and webcast today at 4:30PM Eastern Time
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE
January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients, said Raul Rodriguez, Rigel s president and CEO. These additional resources will contribute significantly to the advancement of our Phase 3 trial. D